Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

コンピュータサイエンス学習プラットフォーム「Recursion」を提供するRecursion, Inc（本社：カリフォルニア州ロサンゼルス、共同創業者：田島慎也 、Jeffry Alvarado、以下当社）は、2020年9月8日、初級編に引き続き、「コンピュータサイエンス基礎：中級編」を ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Wondering if Recursion ...

However, Recursion’s earnings per share (EPS) fell short, posting an actual EPS of -$0.41 against the forecasted -$0.35, resulting in a 17.14% negative surprise. Additionally, Recursion ...